H Lundbeck A/S
CSE:HLUN A
H Lundbeck A/S
Free Cash Flow
H Lundbeck A/S
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Free Cash Flow
kr2.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Free Cash Flow
kr74.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Free Cash Flow
kr18m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Stenocare A/S
CSE:STENO
|
Free Cash Flow
-kr7.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
H Lundbeck A/S
Glance View
Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.
See Also
What is H Lundbeck A/S's Free Cash Flow?
Free Cash Flow
2.8B
DKK
Based on the financial report for Dec 31, 2024, H Lundbeck A/S's Free Cash Flow amounts to 2.8B DKK.
What is H Lundbeck A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
18%
Over the last year, the Free Cash Flow growth was -23%. The average annual Free Cash Flow growth rates for H Lundbeck A/S have been 18% over the past three years .
You don't have any saved screeners yet